Autopsy report · NCT06153420

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

“The study was terminated due to lack of efficacy compared to placebo.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 1 year 7 months before it stopped.
• 421 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

CinPhloro Pharma, LLC

Sponsor type

Industry

Conditions

Irritable Bowel Syndrome With Diarrhea

Interventions

CIN-103; Placebo

Participants

421

Sites

53

Countries

United States

Trials that died the same way

• Dasatinib in Polycythemia Vera
  “This study was terminated due to lack of efficacy.” (86% match in meaning)
• A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
  “The study was early terminated due to lack of efficacy.” (86% match in meaning)
• Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
  “The study was terminated due to lack of efficacy.” (85% match in meaning)
• A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
  “This study was terminated due to a lack of efficacy.” (85% match in meaning)
• Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
  “Study was terminated early due to a lack of improved efficacy.” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.